Articles

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial

Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT, Salzburg, Austria
Dokuz Eylul University, Division of Hematology, Izmir, Turkey
Niguarda Ca’ Granda Hospital, Milan, Italy
Tennessee Oncology, Chattanooga, TN, USA
University of Alberta Hospital, Edmonton, Alberta, Canada
Department of Internal Medicine, Haematology, University Hospital and Medical School Hradec, Králové, Czech Republic
University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
Almazov National Medical Research Centre, St. Petersburg, Russia
Princess Alexandra Hospital, Brisbane, Queensland, Australia
Barts Cancer Institute, London, United Kingdom
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
Sarah Cannon Research Institute, Nashville, TN, USA
Haematologica Early view Jan 13, 2022 https://doi.org/10.3324/haematol.2021.279012